| Literature DB >> 31493069 |
Sabrina A Eltringham1,2, Karen Kilner3, Melanie Gee3, Karen Sage3, Ben D Bray4, Craig J Smith5,6, Sue Pownall7,3.
Abstract
Dysphagia is associated with increased risk of stroke-associated pneumonia (SAP). However, it is unclear what other factors contribute to that risk or which measures may reduce it. This systematic review aimed to provide evidence on interventions and care processes associated with SAP in patients with dysphagia. Studies were screened for inclusion if they included dysphagia only patients, dysphagia and non-dysphagia patients or unselected patients that included dysphagic patients and evaluated factors associated with a recorded frequency of SAP. Electronic databases were searched from inception to February 2017. Eligible studies were critically appraised. Heterogeneity was evaluated using I2. The primary outcome was SAP. Eleven studies were included. Sample sizes ranged from 60 to 1088 patients. There was heterogeneity in study design. Measures of immunodepression are associated with SAP in dysphagic patients. There is insufficient evidence to justify screening for aerobic Gram-negative bacteria. Prophylactic antibiotics did not prevent SAP and proton pump inhibitors may increase risk. Treatment with metoclopramide may reduce SAP risk. Evidence that nasogastric tube (NGT) placement increases risk of SAP is equivocal. A multidisciplinary team approach and instrumental assessment of swallowing may reduce risk of pneumonia. Patients with impaired mobility were associated with increased risk. Findings should be interpreted with caution given the number of studies, heterogeneity and descriptive analyses. Several medical interventions and care processes, which may reduce risk of SAP in patients with dysphagia, have been identified. Further research is needed to evaluate the role of these interventions and care processes in clinical practice.Entities:
Keywords: Deglutition; Deglutition disorders; Dysphagia; Risk factors; Stroke; Stroke-associated pneumonia
Year: 2019 PMID: 31493069 PMCID: PMC7522065 DOI: 10.1007/s00455-019-10061-6
Source DB: PubMed Journal: Dysphagia ISSN: 0179-051X Impact factor: 3.438
Study characteristics
| Author, year, county | Study design | Stroke type | Participants | Intervention | Association with SAP |
|---|---|---|---|---|---|
| Aoki et al. (2016), Japan | Quasi-experimental | Ischemic and hemorrhagic | 132 pre/173 post unselected; Age pre 70.0 ± 12.2 vs. post 70.1 ± 11.5 ( Mdn NIHSS pre 5 (IQR 2–13) vs. 5 (IQR 2–14) post | MDT swallowing approach | aHR 0.41, 95% CI 0.19–0.84, |
| Arai et al. (2017), Japan | Retrospective observational | Ischemic and intracerebral hemorrhage | 335 dysphagia only; Mdn age 82 years (IQR, 74–88 years) Mdn NIHSS 15 (11–24) | Histamine H2-Blocker or PPI or none | RR of H2B 1.24, 95% CI; 0.85–1.81 and 2.00 in PPI, 95% CI 1.12–3.57 |
| Brogan et al. (2015), Australia | Retrospective observational | Unreported | 533 unselected; Age > 80 years. 33.4% | NGT | OR 3.91; 95% CI 1.73–8.80; |
| Gandolfi et al. (2014), Italy | Retrospective observational | Ischemic and hemorrhage | 84 dysphagia only; 39T+ vs. 45T− M (± SD) age 77.9 (8.55). NIHSS 13.88 (7.12) | MDT swallowing approach | aOR 0.34, 95% CI 0.07–1.49 |
| Gosney et al. (2006), UK | RCT double-blind PBO | Unreported | 203 (58 w/dysphagia); Mdn age: active 78 years vs. placebo 62 years. (H1), active 68 years vs. PBO 74 years. (H2), active 71 years vs. PBO 74 years (H3) | SDD oral gel | 7/8 dysphagia patients developed pneumonia ( |
| Hoffman et al. (2016), Germany | Prospective observational | Ischemic | 484 (111 w/ dysphagia); | Screening for SAP, dysphagia and biomarkers | Dysphagia and decreased monocytic HLA-DR predictors of SAP |
| Kalra et al. (2015), UK | Prospective, multicenter, cluster RCT | Ischemic and hemorrhagic | 1088 dysphagia only; | Prophylactic Antibiotics | Algorithm SAP; aOR 1.21; 95% CI 0.71–2.08, |
| Kalra et al. (2016), UK | Prospective, multicenter, cluster RCT | Ischemic and hemorrhagic | 1088 dysphagia only; | NGT | Algorithm SAP; aOR 1.26, 95% CI 0.78–2.03, |
| Langdon et al. (2009), Australia | Prospective observational | Ischemic | 330 unselected; | NGT | aRR 2.76 (95% CI 1.26–6.01), |
| Schwarz et al. (2017), Australia | Retrospective cohort | Ischemic | 110 unselected, Ave age 69.87, range 28–94 | NGT | RR 12.609 (95% CI, OR 21.54), |
| Warusevitaine et al. (2014), UK | Phase II RCT double-blind PBO | Ischemic and hemorrhagic | 60 dysphagia only, | Metoclopramide | aRR 5.24 (95% CI 2.43–11.27), |
Fig. 1Search methodology and outcome